|
Market Closed -
NYSE
20:00:03 30/10/2026 GMT
|
5-day change | 1st Jan Change | ||
| 90.25 USD | -0.09% |
|
-3.44% | +13.72% |
| 10-28 | US estrogen supply crunch widens as women seek alternatives to scarce patches | RE |
| 10-23 | CVS is trying out pharmacists in chronic health management | RE |
| Market Cap | 116B 103B 95.17B 86.24B 161B 10,970B 164B 1,135B 456B 5,770B 434B 424B 18,197B | P/E 2026 * |
13.1x | P/E 2027 * | 12.5x |
|---|---|---|---|---|---|
| Enterprise Value | 167B 150B 138B 125B 234B 15,896B 238B 1,645B 660B 8,362B 628B 615B 26,371B | EV / Sales 2026 * |
0.4x | EV / Sales 2027 * | 0.38x |
| Free-Float |
71.17% | Yield 2026 * |
2.94% | Yield 2027 * | 3.03% |
| Markets | Quality | ||
|---|---|---|---|
NYSE
| CVS | Delayed | |
CBOE
| CVS | Real-time | |
|
Tradegate
| CVS | Real-time | |
|
Mexican S.E.
| CVS * | End-of-day quote | |
|
CBOE
| Real-time | ||
|
London S.E.
| 0HRS | Delayed | |
|
Boerse Muenchen
| CVS | Real-time | |
|
Xetra
| CVS | Delayed | |
|
Deutsche Boerse AG
| CVS | Delayed | |
|
Santiago S.E.
| CVSCL | End-of-day quote | |
|
Swiss Exchange
| CVS | Delayed | |
|
CBOE
| 0HRS | Real-time | |
|
Santiago S.E.
| CVS | End-of-day quote | |
|
Borsa Italiana
| 1CVS | End-of-day quote | |
|
Lima
| CVSUS | End-of-day quote | |
|
Wiener Boerse
| CVS | End-of-day quote | |
|
Börse Stuttgart
| CVS | Delayed | |
|
Swiss Exchange
| CVS | Delayed |
Last Transcript: CVS Health Corporation
| 1 day | +1.30% | ||
| 1 week | -3.44% | ||
| Current month | +5.32% | ||
| 1 month | +5.32% | ||
| 3 months | -14.23% | ||
| 6 months | +8.36% | ||
| Current year | +13.72% |
| 1 week | 89.55 |  | 94.77 |
| 1 month | 84.23 | | 95.26 |
| Current year | 69.51 | | 110.68 |
| 1 year | 69.51 | | 110.68 |
| 3 years | 43.56 | | 110.68 |
| 5 years | 43.56 | | 111.25 |
| 10 years | 43.56 | | 111.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
J. Joyner
CEO | Chief Executive Officer | 62 | 16/10/2024 |
Ali Keshavarz
PSD | President | - | - |
Brian Newman
DFI | Director of Finance/CFO | 57 | 11/05/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
C. Brown
BRD | Director/Board Member | 74 | 28/02/2007 |
Anne Finucane
BRD | Director/Board Member | 73 | 19/01/2011 |
| Director/Board Member | 71 | 04/03/2015 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 31/05/26 | Tax | Chief Financial Officer | -2,478 | 0.0002% | ||
| 31/05/26 | Tax | Chief Technology Officer | -7,618 | 0.0006% | ||
| 21/05/26 | Glenview Capital Management LLC
| Sell | Company | -748,462 | 0.0584% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.09% | -3.44% | +17.68% | +32.70% | 116B | |
| -1.02% | +0.89% | +1.37% | +111.87% | 104B | |
| -4.98% | +2.56% | +114.42% | +1,003.33% | 62.85B | |
| -1.84% | +9.86% | +43.22% | +82.37% | 29.89B | |
| +0.96% | +3.74% | -7.04% | +92.23% | 29.55B | |
| -0.43% | +4.11% | +43.28% | +94.59% | 27.83B | |
| +0.99% | +1.79% | +30.98% | +413.15% | 21.79B | |
| -0.72% | +5.53% | -18.98% | -7.55% | 20.66B | |
| 0.00% | -1.75% | -4.85% | +31.49% | 17.09B | |
| -2.07% | -27.56% | -25.98% | +45.52% | 13.03B | |
| Average | -0.72% | +0.13% | +19.41% | +189.97% | 44.17B | |
| Weighted average by Cap. | -0.66% | +1.19% | +26.09% | +217.81% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 418B 374B 344B 312B 583B 39,693B 594B 4,107B 1,649B 20,880B 1,569B 1,536B 65,847B | 430B 385B 354B 321B 600B 40,834B 611B 4,225B 1,696B 21,480B 1,614B 1,580B 67,740B |
| Net income | 8.87B 7.95B 7.31B 6.62B 12.38B 843B 12.61B 87.19B 35B 443B 33.31B 32.6B 1,398B | 9.32B 8.35B 7.68B 6.96B 13B 885B 13.25B 91.55B 36.75B 465B 34.97B 34.23B 1,468B |
| Net Debt | 51.89B 46.47B 42.75B 38.73B 72.4B 4,927B 73.75B 510B 205B 2,592B 195B 191B 8,173B | 48.85B 43.75B 40.24B 36.46B 68.15B 4,638B 69.43B 480B 193B 2,440B 183B 179B 7,694B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/10/26 | US$90.25 | -0.09% | 8,175,744 |
| 29/10/26 | US$90.33 | +0.42% | 10,231,903 |
| 28/10/26 | US$89.95 | -1.29% | 5,578,371 |
| 27/10/26 | US$91.13 | -1.51% | 4,589,666 |
| 26/10/26 | US$92.53 | -1.01% | 4,257,992 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CVS Stock
Select your edition
All financial news and data tailored to specific country editions
